Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.38
ALXN's Cash to Debt is ranked lower than
88% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 45.69 vs. ALXN: 0.38 )
Ranked among companies with meaningful Cash to Debt only.
ALXN' s Cash to Debt Range Over the Past 10 Years
Min: 0.3  Med: 2.79 Max: No Debt
Current: 0.38
Equity to Asset 0.64
ALXN's Equity to Asset is ranked lower than
54% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ALXN: 0.64 )
Ranked among companies with meaningful Equity to Asset only.
ALXN' s Equity to Asset Range Over the Past 10 Years
Min: 0.04  Med: 0.65 Max: 0.95
Current: 0.64
0.04
0.95
Interest Coverage 6.66
ALXN's Interest Coverage is ranked lower than
88% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALXN: 6.66 )
Ranked among companies with meaningful Interest Coverage only.
ALXN' s Interest Coverage Range Over the Past 10 Years
Min: 6.66  Med: 136.04 Max: 292.93
Current: 6.66
6.66
292.93
F-Score: 6
Z-Score: 4.41
M-Score: -2.47
WACC vs ROIC
9.76%
4.11%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 21.57
ALXN's Operating margin (%) is ranked higher than
87% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -88.05 vs. ALXN: 21.57 )
Ranked among companies with meaningful Operating margin (%) only.
ALXN' s Operating margin (%) Range Over the Past 10 Years
Min: -8798.78  Med: 25.18 Max: 38.89
Current: 21.57
-8798.78
38.89
Net-margin (%) 12.46
ALXN's Net-margin (%) is ranked higher than
83% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. ALXN: 12.46 )
Ranked among companies with meaningful Net-margin (%) only.
ALXN' s Net-margin (%) Range Over the Past 10 Years
Min: -8441.21  Med: 17.12 Max: 76.31
Current: 12.46
-8441.21
76.31
ROE (%) 4.46
ALXN's ROE (%) is ranked higher than
80% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -33.76 vs. ALXN: 4.46 )
Ranked among companies with meaningful ROE (%) only.
ALXN' s ROE (%) Range Over the Past 10 Years
Min: -136.75  Med: 14.48 Max: 63.11
Current: 4.46
-136.75
63.11
ROA (%) 2.81
ALXN's ROA (%) is ranked higher than
81% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: -29.98 vs. ALXN: 2.81 )
Ranked among companies with meaningful ROA (%) only.
ALXN' s ROA (%) Range Over the Past 10 Years
Min: -45.22  Med: 9.66 Max: 46.71
Current: 2.81
-45.22
46.71
ROC (Joel Greenblatt) (%) 49.74
ALXN's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 916 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. ALXN: 49.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALXN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -509.26  Med: 54.85 Max: 173.86
Current: 49.74
-509.26
173.86
Revenue Growth (3Y)(%) 28.30
ALXN's Revenue Growth (3Y)(%) is ranked higher than
79% of the 472 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ALXN: 28.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALXN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 38.8 Max: 462.4
Current: 28.3
0
462.4
EBITDA Growth (3Y)(%) 15.20
ALXN's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. ALXN: 15.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALXN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 22.1 Max: 73.2
Current: 15.2
0
73.2
EPS Growth (3Y)(%) -19.40
ALXN's EPS Growth (3Y)(%) is ranked lower than
67% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. ALXN: -19.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALXN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -19.4  Med: 11 Max: 76
Current: -19.4
-19.4
76
GuruFocus has detected 4 Warning Signs with Alexion Pharmaceuticals Inc $ALXN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALXN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ALXN Guru Trades in Q1 2016

Steven Cohen 85,700 sh (New)
John Paulson 157,200 sh (New)
Joel Greenblatt 10,684 sh (New)
Dodge & Cox 1,820 sh (New)
David Carlson 160,000 sh (unchged)
Samuel Isaly 223,000 sh (unchged)
Louis Moore Bacon Sold Out
Pioneer Investments 41,290 sh (-1.18%)
Ron Baron 55,950 sh (-8.54%)
Frank Sands 5,211,879 sh (-13.95%)
» More
Q2 2016

ALXN Guru Trades in Q2 2016

Manning & Napier Advisors, Inc 95,050 sh (New)
Paul Tudor Jones 13,329 sh (New)
Steven Cohen 529,500 sh (+517.85%)
Joel Greenblatt 58,459 sh (+447.16%)
John Paulson 268,000 sh (+70.48%)
David Carlson 190,000 sh (+18.75%)
Ron Baron 62,249 sh (+11.26%)
Pioneer Investments 41,387 sh (+0.23%)
Samuel Isaly 396,700 sh (+77.89%)
Dodge & Cox Sold Out
Frank Sands 4,874,758 sh (-6.47%)
» More
Q3 2016

ALXN Guru Trades in Q3 2016

Paul Tudor Jones 153,511 sh (+1051.71%)
Steven Cohen 611,500 sh (+15.49%)
Manning & Napier Advisors, Inc 106,610 sh (+12.16%)
Frank Sands 5,245,752 sh (+7.61%)
David Carlson 190,000 sh (unchged)
Pioneer Investments 40,938 sh (-1.08%)
John Paulson 227,700 sh (-15.04%)
Joel Greenblatt 46,797 sh (-19.95%)
Ron Baron 44,260 sh (-28.90%)
Samuel Isaly 183,684 sh (-53.70%)
» More
2016

ALXN Guru Trades in 2016

Spiros Segalas 2,581,555 sh (-1.28%)
» More
» Details

Insider Trades

Latest Guru Trades with ALXN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 8731
Compare:OTCPK:ALIOY, NAS:INCY, NAS:REGN, NAS:VRTX, OTCPK:CSLLY, NAS:BMRN, OTCPK:UCBJY, NAS:GRFS, OTCPK:GMXAY, OTCPK:NVZMY, OTCPK:SHPGF, NAS:ALKS, NAS:SGEN, NAS:TSRO, NAS:JAZZ, NAS:UTHR, NAS:IONS, OTCPK:SBMFF, NAS:EXEL, NAS:ARIA » details
Traded in other countries:AXP.Germany, ALXN.Switzerland, 0QZM.UK,
Alexion Pharmaceuticals Inc is a biopharmaceutical company engaged in serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Alexion Pharmaceuticals Inc is a Delaware based company, incorporated in 1992. The Company is a bio-pharmaceutical company serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria, an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome, an ultra-rare and life-threatening genetic disease. The Company is also evaluating other potential indications for Soliris in other diseases in which chronic uncontrolled complement activation is the underlying mechanism. It operates in United States, Europe and Asia Pacific. It competes with companies that produce and market synthetic compounds and with specialized biotechnology firms in the United States, Europe and in other countries and regions, as well as a growing number of large pharmaceutical companies that are developing biotechnology products. The preclinical studies and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of products and product candidates, including Soliris, are subject to extensive regulation by governmental authorities in the United States, the European Union and other territories.

Guru Investment Theses on Alexion Pharmaceuticals Inc

Spiros Segalas on Alexion Pharmaceuticals - Aug 18, 2016



Many Health Care stocks that have been strong positive contributors to return over past quarters continued to face concerns about drug pricing. Biotechnology companies that sell innovative, high priced drugs lost ground, including Alexion Pharmaceuticals (NASDAQ:ALXN). We believe that the long-term fundamentals of the Fund’s biotechnology holdings remain intact, and that current valuations underestimate the potential of pipeline drugs.





From Spiros Segamas' Armiel Appreciation second quarter 2016 commentary.



Check out Spiros Segalas latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals - May 23, 2016

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) fell in the first quarter as a result of the significant correction in the biotech/pharma space. Alexion develops treatments for rare diseases. Its high foreign exchange exposure and high multiple also pressured the stock. Overall, we believe there have been no significant changes to the fundamentals of Alexion’s investment thesis (innovative, exceptionally well-managed company with unique assets and pricing power) and we retain conviction.



From Baron Fifth Avenue Growth Fund first quarter commentary 2016.



Check out Ron Baron latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals - May 23, 2016

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) fell in the first quarter as a result of the significant correction in the biotech/pharma space. Alexion develops treatments for rare diseases. Its high foreign exchange exposure and high



From Baron Fifth Avenue Growth Fund first quarter commentary 2016.



Check out Ron Baron latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals - May 06, 2016

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) fell sharply in the first quarter as a result of the massive correction in the biotech/pharma space. Alexion develops treatments for rare diseases. Its high foreign exchange exposure and high multiple also pressured the stock. Overall, we believe there have been no significant changes to the fundamentals of Alexion’s story and we retain conviction. (Josh Riegelhaupt)





From Baron Opportunity Fund first quarter 2016 commentary.







Check out Ron Baron latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals - Feb 08, 2016

We also sold our Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) position in the third quarter to harvest a tax loss. We rebuilt our position this quarter. Alexion is the premier orphan disease company, whose lead product Soliris is a lifesaving medicine for both Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The company has expanded its efforts in orphan diseases (particularly ones with high unmet needs) with the acquisition of Strensiq for Hypophosphatasia (HPP) and Kanuma for Lysosomal Acid Lipase Deficiency (LAL-D), both of which are approved or in the final stages of approval for launch worldwide.



From the Baron Funds Opportunity Fund fourth quarter 2015 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals Inc. - Nov 10, 2015

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is the premier orphan disease company, whose lead product Soliris is a lifesaving medicine for both Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical hemolytic uremic syndrome (aHUS). The company has expanded its efforts in orphan diseases (particularly ones with high unmet needs) with the acquisition of Strensiq for HPP (Hypophosphatasia) and Kanuma for LAL-D (Lysosomal Acid Lipase Deficiency), both of which are approved or in the final stages of approval for launch worldwide. The company recently announced the delay of Strensiq approval by the FDA for manufacturing related issues. With greater uncertainty surrounding the approval of Strensiq, and overall sentiment on the biotech industry souring, we reduced our exposure to the industry and sold our position in Alexion.





From the Baron Opportunity Fund third quarter 2015 letter.



Check out Ron Baron latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals Inc. - Aug 19, 2015

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is a biopharmaceutical company that pioneered the “orphan disease” space by focusing on delivering life-transforming treatments for patients with devastating (life threatening) and ultra-rare (or orphan) diseases. Alexion is a leader in disease education and diagnostic initiatives to ensure that patients for its drugs are rapidly and accurately diagnosed. We believe Alexion’s first commercial drug, known as Soliris, which is used to treat paroxysmal nocturnal hemoglobinuria (called PNH) and atypical hemolytic uremic syndrome (referred to as aHUS), continues to possess a large global growth opportunity. Alexion has a pipeline of additional rare-disease treatments, and recently acquired Synageva, a company with two additional drugs for treating rare and devastating metabolic diseases, as well as a pipeline of other compounds, giving the company what we believe to be the most robust rare disease pipeline in the biotech industry.





From Baron Funds’ second quarter 2015 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Alexion Pharmaceuticals Inc

Spiros Segalas on Alexion Pharmaceuticals Guru stock highlight
Many Health Care stocks that have been strong positive contributors to return over past quarters continued to face concerns about drug pricing. Biotechnology companies that sell innovative, high priced drugs lost ground, including Alexion Pharmaceuticals (NASDAQ:ALXN). We believe that the long-term fundamentals of the Fund’s biotechnology holdings remain intact, and that current valuations underestimate the potential of pipeline drugs.


From Spiros Segamas' Armiel Appreciation second quarter 2016 commentary. Read more...
Baron Funds Comments on Alexion Pharmaceuticals Guru stock highlight
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) fell in the first quarter as a result of the significant correction in the biotech/pharma space. Alexion develops treatments for rare diseases. Its high foreign exchange exposure and high Read more...
Baron Funds Comments on Alexion Pharmaceuticals Guru stock highlight
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) fell in the first quarter as a result of the significant correction in the biotech/pharma space. Alexion develops treatments for rare diseases. Its high foreign exchange exposure and high multiple also pressured the stock. Overall, we believe there have been no significant changes to the fundamentals of Alexion’s investment thesis (innovative, exceptionally well-managed company with unique assets and pricing power) and we retain conviction. Read more...
Baron Funds Comments on Alexion Pharmaceuticals Guru stock highlight
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) fell sharply in the first quarter as a result of the massive correction in the biotech/pharma space. Alexion develops treatments for rare diseases. Its high foreign exchange exposure and high multiple also pressured the stock. Overall, we believe there have been no significant changes to the fundamentals of Alexion’s story and we retain conviction. (Josh Riegelhaupt) Read more...
Baron Funds Comments on Alexion Pharmaceuticals Guru stock highlight
We also sold our Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) position in the third quarter to harvest a tax loss. We rebuilt our position this quarter. Alexion is the premier orphan disease company, whose lead product Soliris is a lifesaving medicine for both Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The company has expanded its efforts in orphan diseases (particularly ones with high unmet needs) with the acquisition of Strensiq for Hypophosphatasia (HPP) and Kanuma for Lysosomal Acid Lipase Deficiency (LAL-D), both of which are approved or in the final stages of approval for launch worldwide. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 80.47
ALXN's P/E(ttm) is ranked lower than
81% of the 246 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. ALXN: 80.47 )
Ranked among companies with meaningful P/E(ttm) only.
ALXN' s P/E(ttm) Range Over the Past 10 Years
Min: 13.83  Med: 78.42 Max: 961.82
Current: 80.47
13.83
961.82
Forward P/E 25.58
ALXN's Forward P/E is ranked lower than
67% of the 61 Companies
in the Global Biotechnology industry.

( Industry Median: 17.86 vs. ALXN: 25.58 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 80.47
ALXN's PE(NRI) is ranked lower than
81% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 28.58 vs. ALXN: 80.47 )
Ranked among companies with meaningful PE(NRI) only.
ALXN' s PE(NRI) Range Over the Past 10 Years
Min: 13.71  Med: 77.68 Max: 705.33
Current: 80.47
13.71
705.33
Price/Owner Earnings (ttm) 62.55
ALXN's Price/Owner Earnings (ttm) is ranked lower than
70% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 28.43 vs. ALXN: 62.55 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ALXN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 15.74  Med: 68.84 Max: 1108.89
Current: 62.55
15.74
1108.89
P/B 3.47
ALXN's P/B is ranked higher than
50% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 3.62 vs. ALXN: 3.47 )
Ranked among companies with meaningful P/B only.
ALXN' s P/B Range Over the Past 10 Years
Min: 2.99  Med: 10.38 Max: 166.91
Current: 3.47
2.99
166.91
P/S 9.99
ALXN's P/S is ranked higher than
52% of the 682 Companies
in the Global Biotechnology industry.

( Industry Median: 10.89 vs. ALXN: 9.99 )
Ranked among companies with meaningful P/S only.
ALXN' s P/S Range Over the Past 10 Years
Min: 8.6  Med: 16.21 Max: 929.17
Current: 9.99
8.6
929.17
PFCF 50.29
ALXN's PFCF is ranked lower than
73% of the 120 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. ALXN: 50.29 )
Ranked among companies with meaningful PFCF only.
ALXN' s PFCF Range Over the Past 10 Years
Min: 40  Med: 61.94 Max: 3326.67
Current: 50.29
40
3326.67
POCF 33.04
ALXN's POCF is ranked lower than
66% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 21.07 vs. ALXN: 33.04 )
Ranked among companies with meaningful POCF only.
ALXN' s POCF Range Over the Past 10 Years
Min: 28.45  Med: 48.29 Max: 83.31
Current: 33.04
28.45
83.31
EV-to-EBIT 48.85
ALXN's EV-to-EBIT is ranked lower than
80% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 20.60 vs. ALXN: 48.85 )
Ranked among companies with meaningful EV-to-EBIT only.
ALXN' s EV-to-EBIT Range Over the Past 10 Years
Min: -115.8  Med: 47 Max: 499.4
Current: 48.85
-115.8
499.4
EV-to-EBITDA 30.42
ALXN's EV-to-EBITDA is ranked lower than
70% of the 264 Companies
in the Global Biotechnology industry.

( Industry Median: 17.09 vs. ALXN: 30.42 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALXN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -145  Med: 42 Max: 258.3
Current: 30.42
-145
258.3
PEG 2.27
ALXN's PEG is ranked lower than
54% of the 98 Companies
in the Global Biotechnology industry.

( Industry Median: 2.14 vs. ALXN: 2.27 )
Ranked among companies with meaningful PEG only.
ALXN' s PEG Range Over the Past 10 Years
Min: 0.68  Med: 1.71 Max: 11.71
Current: 2.27
0.68
11.71
Shiller P/E 125.05
ALXN's Shiller P/E is ranked lower than
82% of the 56 Companies
in the Global Biotechnology industry.

( Industry Median: 46.84 vs. ALXN: 125.05 )
Ranked among companies with meaningful Shiller P/E only.
ALXN' s Shiller P/E Range Over the Past 10 Years
Min: 107.19  Med: 266.13 Max: 1466
Current: 125.05
107.19
1466
Current Ratio 2.51
ALXN's Current Ratio is ranked lower than
68% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ALXN: 2.51 )
Ranked among companies with meaningful Current Ratio only.
ALXN' s Current Ratio Range Over the Past 10 Years
Min: 2.3  Med: 6.22 Max: 52.92
Current: 2.51
2.3
52.92
Quick Ratio 2.16
ALXN's Quick Ratio is ranked lower than
68% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. ALXN: 2.16 )
Ranked among companies with meaningful Quick Ratio only.
ALXN' s Quick Ratio Range Over the Past 10 Years
Min: 2.03  Med: 6.02 Max: 52.92
Current: 2.16
2.03
52.92
Days Inventory 444.84
ALXN's Days Inventory is ranked lower than
93% of the 437 Companies
in the Global Biotechnology industry.

( Industry Median: 127.64 vs. ALXN: 444.84 )
Ranked among companies with meaningful Days Inventory only.
ALXN' s Days Inventory Range Over the Past 10 Years
Min: 202.61  Med: 365.11 Max: 959.95
Current: 444.84
202.61
959.95
Days Sales Outstanding 83.63
ALXN's Days Sales Outstanding is ranked lower than
65% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 62.07 vs. ALXN: 83.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALXN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 70.74  Med: 106.12 Max: 339.23
Current: 83.63
70.74
339.23
Days Payable 65.92
ALXN's Days Payable is ranked higher than
55% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. ALXN: 65.92 )
Ranked among companies with meaningful Days Payable only.
ALXN' s Days Payable Range Over the Past 10 Years
Min: 44.39  Med: 92.41 Max: 494.52
Current: 65.92
44.39
494.52

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.00
ALXN's 3-Year Average Share Buyback Ratio is ranked higher than
71% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.20 vs. ALXN: -5.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALXN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -24.9  Med: -11.2 Max: -2.4
Current: -5
-24.9
-2.4

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.28
ALXN's Price/Projected FCF is ranked higher than
61% of the 157 Companies
in the Global Biotechnology industry.

( Industry Median: 2.91 vs. ALXN: 2.28 )
Ranked among companies with meaningful Price/Projected FCF only.
ALXN' s Price/Projected FCF Range Over the Past 10 Years
Min: 2.12  Med: 5.44 Max: 142.22
Current: 2.28
2.12
142.22
Price/Median PS Value 0.61
ALXN's Price/Median PS Value is ranked higher than
74% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ALXN: 0.61 )
Ranked among companies with meaningful Price/Median PS Value only.
ALXN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.38  Med: 1.23 Max: 53.16
Current: 0.61
0.38
53.16
Price/Peter Lynch Fair Value 3.22
ALXN's Price/Peter Lynch Fair Value is ranked lower than
67% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 1.63 vs. ALXN: 3.22 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ALXN' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.56  Med: 2.97 Max: 11.39
Current: 3.22
0.56
11.39
Earnings Yield (Greenblatt) (%) 2.00
ALXN's Earnings Yield (Greenblatt) (%) is ranked higher than
79% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. ALXN: 2.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALXN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 2 Max: 3
Current: 2
0.2
3
Forward Rate of Return (Yacktman) (%) 30.66
ALXN's Forward Rate of Return (Yacktman) (%) is ranked higher than
75% of the 118 Companies
in the Global Biotechnology industry.

( Industry Median: 15.03 vs. ALXN: 30.66 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ALXN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -18.5  Med: 0.5 Max: 75.6
Current: 30.66
-18.5
75.6

More Statistics

Revenue (TTM) (Mil) $2,954
EPS (TTM) $ 1.64
Beta1.05
Short Percentage of Float3.44%
52-Week Range $109.12 - 162.65
Shares Outstanding (Mil)223.93

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 3,094 3,524 4,317 5,234
EPS ($) 4.62 5.21 7.02 9.16
EPS w/o NRI ($) 4.62 5.21 7.02 9.16
EPS Growth Rate
(3Y to 5Y Estimate)
14.63%
Dividends Per Share ($)
» More Articles for ALXN

Headlines

Articles On GuruFocus.com
Spiros Segalas on Alexion Pharmaceuticals Aug 18 2016 
Spiros 'Sig' Segalas' Capital Appreciation Fund 2nd Quarter Commentary Nov 07 2016 
Frank Sands Sells Visa, Baidu, Alibaba May 24 2016 
Baron Funds Comments on Alexion Pharmaceuticals May 23 2016 
Baron Funds Comments on Alexion Pharmaceuticals May 23 2016 
Baron Funds Comments on Alexion Pharmaceuticals May 06 2016 
Baron Funds Comments on Alexion Pharmaceuticals Feb 08 2016 
Weekly CFO Sales Highlight: H&R Block, DISH Network, Alexion Pharmaceuticals Jan 03 2016 
Weekly CFO Sells Highlight: Tyson Foods, Alexion Pharmaceuticals, Gilead Sciences Dec 13 2015 
Weekly Insider Sells Highlights: CDW, Twitter, P&G, Alexion Pharmaceuticals Dec 10 2015 

More From Other Websites
[$$] Drugmakers alarmed by Trump pricing threat Jan 14 2017
ALEXION 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and... Jan 13 2017
FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Jan 13 2017
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Alexion... Jan 12 2017
Trump takes aim at pharma Jan 12 2017
Here Is Why Red-Hot Alexion Is Only Suitable for Risk Takers Now Jan 11 2017
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Jan 11 2017
JPMorgan Makes Big Changes to US Analyst Focus List for January Jan 11 2017
Alexion (ALXN) Files for Label Expansion of Soliris in U.S., EU Jan 11 2017
ALEXION PHARMACEUTICALS INC Financials Jan 10 2017
Alexion Seeks Expanded Use for Soliris in US and EU Jan 10 2017
Blog Coverage Alexion Pharma Applies for US and EU Marketing Approval of Refractory Generalized... Jan 10 2017
Mysterious $5 Billion Biotech Firm Moderna Lays Out Drug Pipeline Jan 09 2017
Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference Jan 09 2017
Alexion Blood Disorder Meds Wins Orphan Drug Status Jan 09 2017
Alexion CEO: 'We're moving on' from shakeup Jan 09 2017
Bullish and Bearish Reversals in the Market Jan 09 2017
Lawsuit for Investors in Shares of Alexion Pharmaceuticals, Inc. (ALXN) Announced by Shareholders... Jan 09 2017
Alexion Blood Disorder Drug Gets Orphan Designation in U.S. Jan 09 2017
Alexion Submits U.S. and EU Applications Seeking Approval of Soliris® (Eculizumab) as a Treatment... Jan 09 2017
INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Alexion... Jan 07 2017
FDA Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal... Jan 06 2017
Alexion Pharmaceuticals Files Form 10-Q for Third Quarter 2016 Jan 04 2017
Alexion Announces Top-Line Results from Phase 2/3 PROTECT Study of Eculizumab (Soliris®) for the... Dec 21 2016
Shakeup at Alexion Pharmaceuticals hits stock price Dec 12 2016
Shakeup at Alexion Pharmaceuticals hits stock price Dec 12 2016
Shakeup at Alexion Pharmaceuticals hits stock price Dec 12 2016
Shakeup at Alexion Pharmaceuticals hits stock price Dec 12 2016
Alexion Provides Update on Form 10-Q Filing Nov 09 2016
Alexion Initiates Simultaneous Registration Trials of ALXN1210 for Patients with Paroxysmal... Oct 27 2016
Alexion Reports Third Quarter 2016 Results Oct 27 2016
FDA Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host... Oct 19 2016
Alexion Pharmaceuticals to Report Third Quarter 2016 Results on Thursday, October 27, 2016 Oct 10 2016
New Long-Term Data Presented at WCPGHAN 2016 Show Rapid and Sustained Improvements in Important... Oct 06 2016
Alexion Employees Volunteer Together in Company’s First Global Day of Service Sep 23 2016
Alexion Employees Volunteer Together in Company’s First Global Day of Service Sep 23 2016
Alexion Employees Volunteer Together in Company’s First Global Day of Service Sep 23 2016
UK okays Alexion drug costing up to $2 mln but wants price cut Sep 22 2016
UK okays Alexion drug costing up to $2 mln but wants price cut Sep 22 2016
Alexion Launches Uncommon Strength Campaign to Unite and Celebrate the Courage and Resilience of... Sep 13 2016
Alexion to Present at Upcoming Investor Conferences Sep 06 2016
European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with... Aug 29 2016
Alexion Reports Second Quarter 2016 Results Jul 28 2016
Alexion Presents New SBC-103 (rhNAGLU enzyme) Phase 1/2 Data on Brain MRI and Neurocognitive... Jul 14 2016
Alexion Pharmaceuticals to Report Second Quarter 2016 Results on Thursday, July 28, 2016 Jul 11 2016
New Data from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized... Jul 07 2016
Late-Breaking Data Presented at EHA: All Patients with PNH Treated with Once-Monthly Dosing of... Jun 10 2016
Sanofi launches $9.3 billion fight for U.S. cancer firm Medivation Apr 28 2016
Sanofi launches $9.3 bln fight for U.S. cancer firm Medivation Apr 28 2016
UK cost agency queries value of $700,000-a-year Alexion drug Feb 18 2016
UK cost agency queries value of $700,000-a-year Alexion drug Feb 17 2016
Alexion's $550,000 bone drug too expensive for Britain Dec 02 2015
Germany, U.S. in hot pursuit of "messenger" drug molecules Nov 12 2015
Alexion gets EU approval for drug acquired in Synageva deal Sep 01 2015
Alexion gets EU approval for drug acquired in Synageva deal Sep 01 2015
Alexion to bolster rare disease offering with $8.4 billion deal May 06 2015
US stocks drop on jobs data, Yellen's warning on values May 06 2015
Deals of the day- Mergers and acquisitions May 06 2015
Alexion to bolster rare disease offering with $8.4 billion deal May 06 2015
US stocks drop in volatile trade on weak jobs data May 06 2015
Alexion to buy Synageva BioPharma in $8.4 billion deal May 06 2015
US stocks rise on big biopharma merger May 06 2015
US STOCKS-Wall St rallies, S&P back above 14-day moving average Sep 24 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)